balovaptan inntooltip international nonproprietary name developmental code name selective small molecule antagonist vasopressin receptor development roche treatment posttraumatic stress phase iii clinical trial adults phase ii clinical trial children january roche announced us food drug administration fda granted breakthrough therapy designation balovaptan individuals autism spectrum disorder fda granted based results adult phase ii clinical trial called vanilla vasopressin antagonist improve social communication autism phase iii adult study march called currentlyclosed august phase ii child study called needed also phase ii studies treatment stroke however since discontinued indications developed posttraumatic stress disorder plans submit regulatory filings drug article relating nervous system stub help wikipedia expanding httpsenwikipediaorgwikibalovaptan